0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD34

CD34

Brief Information

Name:Hematopoietic progenitor cell antigen CD34
Target Synonym:CD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD4-H52H9 Human Human CD34 Protein, His Tag
CD4-H52H9-structure
CD4-H52H9-sds

Synonym Name

CD34,RP11-328D5.2

Background

CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anti-CD34 mab-sirolimus (OrbusNeich) Approved Orbusneich Coronary Restenosis Orbusneich 2013-01-01 Coronary Restenosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Stem cell therapeutics (ExCellThera) ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 Phase 2 Clinical Excellthera Hematologic Neoplasms; Multiple Myeloma; Leukemia, Myeloid, Acute Details
Autologous peripheral blood stem cell therapy (CellProthera) Phase 2 Clinical Cellprothera Myocardial Infarction Details
CLBS-12 CLBS-12 Phase 2 Clinical Caladrius Biosciences Atherosclerosis; Thromboangiitis Obliterans; Ischemia Details
GSK-2696277 GSK-2696277 Phase 2 Clinical Glaxosmithkline Plc, Ospedale San Raffaele, Fondazione Telethon Thalassemia Details
RTX-134 RTX-134 Phase 1 Clinical Rubius Therapeutics Phenylketonurias Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) Phase 1 Clinical University Health Network Fabry Disease Details
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) Phase 2 Clinical Genenta Science Glioblastoma; Multiple Myeloma Details
Dilanubicel (Nohla Therapeutics) NLA-101 Phase 3 Clinical Fred Hutchinson Cancer Research Center Leukemia; Leukemia, Myeloid; Leukemia, Erythroblastic, Acute; Hematologic Diseases; Communicable Diseases; Neutropenia; Leukemia, Myelomonocytic, Acute; Graft vs Host Disease; Leukemia, Megakaryoblastic, Acute; Acute Radiation Syndrome; Leukemia, Myeloid, Acute; Leukemia, Monocytic, Acute Details
HSC-100 HSC-100 Phase 1 Clinical Tatcitus Therapeutics, Mount Sinai Health System Hematologic Neoplasms Details
shRNA-modified CD34 cell therapy (Kanglin Biotech) Phase 1 Clinical Kanglin Biotech (Hangzhou) Co Ltd HIV Infections Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) Phase 2 Clinical Ucla Biomedical Library Adenosine deaminase deficiency Details
Autologous stem cell therapy (Shire) Phase 3 Clinical Shire Development Llc Myocardial Ischemia; Peripheral Vascular Diseases; Angina Pectoris; Coronary Disease Details
MB-107 MB-107; IND-14570 Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad, St. Jude Children'S Research Hospital, National Heart, Lung And Blood Institute Immunologic Deficiency Syndromes Details

This web search service is supported by Google Inc.

totop